Phase 4
N=11
Effect of Fosaprepitant on Motor Evoked and Somatosensory Evoked Potentials Under General Anesthesia
Postoperative Nausea
Bottom Line
View on ClinicalTrials.gov: NCT03197064 ↗Enrolled (actual)
11
Serious AEs
0.0%
Results posted
Jul 2022
Primary outcome: Primary: Somatosensory Evoked Potentials (SEPs), Extremity Amplitude (Left Upper Extremity) — 2.685; 2.545; 2.58; 2.292 µV — p=0.35
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Fosaprepitant 150 mg (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Stanford University
- Primary completion
- Jan 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Somatosensory Evoked Potentials (SEPs), Extremity Amplitude (Left Upper Extremity) |
2.685; 2.545; 2.58; 2.292 | 0.35 |
| PRIMARY Somatosensory Evoked Potentials (SEPs), Extremity Amplitude (Right Upper Extremity) |
2.38; 2.47; 2.27; 2.47 | 0.72 |
| PRIMARY Somatosensory Evoked Potentials (SEPs), Extremity Amplitude (Left Lower Extremity) |
1.56; 1.56; 1.47; 1.35 | 0.93 |
| PRIMARY Somatosensory Evoked Potentials (SEPs), Extremity Amplitude (Right Lower Extremity) |
1.7; 1.77; 1.81; 1.79 | 0.42 |
| PRIMARY Motor Evoked Potentials Amplitude (Left Upper Extremity) |
1300; 1573.33; 1634.89; 1544.78 | 0.386 |
Summary
The purpose of this study is to determine if intravenous fosaprepitant can interfere with nervous system monitoring signals in patients having surgery under general anesthesia. This medication has numerous effects on the sensory nerve transmission which can theoretically have effects on the ability to accurately measure somatosensory evoked potentials.
Eligibility Criteria
Inclusion Criteria
- Having a surgical procedure requiring general anesthesia, having a surgical procedure where neuromonitoing with somatosensory evoked potentials and motor evoked potentials neuromonitoring is requested by the surgical team
Exclusion Criteria
- Patient refusal, allergy to the drug or any of its excipients, pre-operative motor or sensory deficit
Data sourced from ClinicalTrials.gov (NCT03197064). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.